BIO Statement on the FDA’s ‘Fit-for-Purpose Rare…
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on the FDA’s ‘Fit-for-Purpose Rare Disease Framework Initiative.’“Today’s announcement is an important step…
